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Background: The frequent occurrences of antibiotic-resistant biofilm forming pathogens have become global issue
since various measures that had been taken to curb the situation led to failure. Euphorbia hirta, is a well-known
ethnomedicinal plant of Malaysia with diverse biological activities. This plant has been used widely in traditional
medicine for the treatment of gastrointestinal, bronchial and respiratory ailments caused by infectious agents.
Methods: In the present study, chemical compositions of methanol extract of E. hirta L. aerial part was analyzed by
gas chromatography and gas chromatography coupled to mass spectrometry. A relevant in vitro model was
developed to assess the potency of the E. hirta extract to inhibit the bacterial biofilm formation as well as to
eradicate the established biofilms. Besides biofilm, E. hirta extract was also evaluated for the inhibition efficacy on
planktonic cells using tetrazolium microplate assay. For these purposes, a panel of clinically resistant pathogens and
American type culture collection (ATCC) strains were used.
Results: The methanolic extract of aerial part of E. hirta was predominantly composed of terpenoid (60.5%) which
is often regarded as an active entity accountable for the membrane destruction and biofilm cell detachment. The
highest antibacterial effect of crude E. hirta extract was observed in the clinical isolates of Pseudomonas aeruginosa
with minimum inhibitory concentration (MIC) value of 0.062 mg/ml. The extract also displayed potent biofilm
inhibition and eradication activity against P. aeruginosa with minimum biofilm inhibition concentration (MBIC) and
minimum biofilm eradication concentration (MBEC) values of 0.25 mg/ml and 0.5 mg/ml, respectively.
Conclusions: The crude methanol extract of E. hirta has proven to have interesting and potential anti-biofilm
properties. The findings from this study will also help to establish a very promising anti-infective phytotherapeutical
to be exploited in the pharmaceutical industries.
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Ever since the advent of humanity on earth, plants have
served unlimited source of phytotherapeuticals for various
diseases [1]. In recent years, the emergence of biofilm in-
fections have generated an urgent alarm in research and
development field in seeks for novel antimicrobials from
ethnomedicinal plant. National Institutes of Health (NIH)
has estimated 70% of all microbial infections in the world
are associated with biofilms [2]. Biofilms are developed by* Correspondence: angelpriya30@hotmail.com
School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden,
Penang, Malaysia
© 2013 Perumal and Mahmud; licensee BioMe
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.planktonic microorganisms aggregating together forming
thin layer. Soon, close contact of few layers of microor-
ganisms grow into dense, three dimensional structures
accommodating millions of planktonic cells operating mu-
tually to form a shield called biofilm. To date, the most
common medically significant biofilm infections include
eye, middle ear, urogenital tract, gastrointestinal tract, lung
tissue and teeth [3]. Biofilms also accounted responsible
for majority of contamination in the hospital devises and
medical implants such as peritoneal membrane and dialy-
sis catheters, indwelling catheters for chronic administra-
tion of chemotherapeutic agents, tracheal and ventilator
tubing, prostheses, dental implants and cardiac implantsd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ing within are vastly resistant up to 1000 fold higher to po-
tent antibacterial agents which are used as a last resort,
including methicillin and vancomycin [5]. In contrast the
same bacteria grown under planktonic forms are suscep-
tible to those antibiotics.
Euphorbia hirta L., a member of the Euphorbiaceae
family, is a common weed distributed in the temperate,
sub-tropical, and tropical regions of the world. It is alter-
natively known by its Malay names as ‘ara tanah’ and
‘gelang susu’. This plant has been used in traditional
Malay medicine for many years. The folk medicine used
it in the treatment of gastrointestinal disorders, particu-
larly intestinal parasitotosis, amoebic dysentery, diarrhoea,
and ulcer [6,7]. The plant is also used in the treatment of
bronchial and respiratory disorders including asthma,
bronchitis, and hay fever. E. hirta is proven for well ac-
cepted pharmacological activities such as antioxidant [8],
antibacterial [9,10], antifungal [11], diuretic [12], anthel-
mintic [13], antihypertensive [12], anxiolytic [14], antimal-
arial [15], anti-inflammatory [16], and anticancer [8].
Despite the various researches concerning the evalu-
ation of multiple bioactivities, none have dealt with the
bacterial biofilm investigation from E. hirta. Therefore,
the aim of this study is to analyze the potency of E. hirta
extracts as potential biofilm inhibitor and biofilm eradica-
tor crude drugs as well as to comprehensively characterize
the methanolic extract of E. hirta aerial part grown in
Malaysia. A modified version of microdilution assay was
developed in this investigation to measure the inhibition
of biofilm formation and biofilm eradication activities from
E. hirta L. against clinical isolates and standard strains.
From our literature search, there has been no compre-
hensive chemical composition data on the methanolic
extract of E. hirta aerial part has been reported or evalu-
ated. Moreover, the possibility is higher that of same spe-
cies from different countries could show different chemical
composition and biological activity. Therefore the present
study is assumed the first to report fingerprinting profiles
of E. hirta aerial part by GCMS-MS as well as the initial re-
search to assess on biofilm inhibitory and eradication activ-
ity of this ethnomedicinal plant.
Methods
Chemicals and reagents
p-iodonitrotetrazolium violet (INT) were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). All other
chemicals, namely dimethylsulfoxide (DMSO) and metha-
nol were of analytical grade and obtained from Merck
(Darmstadt, Germany).
Plant collection and authentication
The fresh aerial parts of Euphorbia hirta L. were ob-
tained from Relau, Penang City, Malaysia. The plant wascollected during the period of July to August 2012. The
plant was authenticated by Mr. Shunmugam, the botan-
ist of the School of Biological Sciences, Universiti Sains
Malaysia, where a voucher specimen (No.11254) was de-
posited in the Herbarium Unit of the school.
Extraction of plant material
Aerial parts of E. hirta were air-dried and ground to
mesh size No.40 and macerated solely with methanol by
ratio of 10 g of ground plant material in 100 ml of
methanol. Extraction was done for 6 days under occa-
sional shaking and the process was repeated three times.
The combined extracts obtained were filtered and con-
centrated to dryness with a rotary evaporator (Rotavapor®
R-200, Buchi, Switzerland) under reduced pressure. The ex-
tract obtained was eventually freeze-dried (FreeZone®, MO)
to remove any residual water. The yield of extract was cal-
culated. The extractive procedure was performed in dim
lighting and all the dried extracts were stored at 4°C until
use. For GCMS analysis, sample was prepared by dissolving
in methanol to obtain a concentration of 1 mg/ml. The
sample was filtered through 0.22 μm syringe filter devices
(Milipore) prior to injecting in the chromatography system.
Gas chromatography (GC) and gas chromatography mass
spectrometry (GC/MS) analysis
The methanol extract of E. hirta was analyzed by GC
and GC–MS using an Agilent-Technologies 6890 N Net-
work GC system equipped with an Agilent-Technologies
5973 MSD mass spectrometer and Agilent-Technologies
7683B series auto injector. The GC/MS was operated under
the following conditions. Separation was performed on HP-
5MS capillary column (30 m× 0.25 mm× film thickness
0.25 μm). The column temperature was programmed from
70°C to 280°C at a rate of 20°C /min with the lower and
upper temperatures being held for 3 and 10 min, respect-
ively. The GC injector and MS transfer line temperatures
were set at 250°C and 280°C, respectively. GC was per-
formed in the splitless mode. Helium was used as carrier
gas at a flow rate of 1.1 ml/min. For MS detection, the elec-
tron ionization mode with ionization energy of 70 eV was
used, with a mass range at m/z 30–650. An injection vol-
ume of 1 μl was used for the methanol extract. The compo-
nents were identified by their retention times and based on
the commercially available spectral, (National Institute of
Standards and Technology (NIST) mass spectral search
program for NIST/EPA/NIH Mass Spectral Library V2.0)
and mass fragmentation patterns using data of standards at
Wiley 7.0 Library. GC and GC–MS analyses were per-
formed in triplicate.
Bacterial strains
The susceptibility test comprises a panel of clinically re-
sistant Gram-negative and Gram-positive bacteria. These
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biofilms and causes severe infections. The panel of clin-
ically resistant pathogens used in this study includes
Klebsiella pneumonia, Pseudomonas aeruginosa, Sal-
monella typhi, Shigella dysenteriae, Enterobacter aero-
gens, Escherichia coli, Enterococcus faecalis, Proteus
mirabilis, Proteus vulgaris, Bacillus subtilis and Bacillus
cereus. The clinical isolates were obtained from Depart-
ment of Medical Microbiology and Parasitology (JTMP),
School of Medical Sciences, Universiti Sains Malaysia,
and stored at −80°C in tryptic soy broth containing 50%
glycerol. Their identities were confirmed by biochemical
test using API (analytical profile index) system. The
bioassays was also performed in parallel with well char-
acterized strains obtained from the American Type Cul-
ture Collection (ATCC), including Escherichia coli (ATCC
25922), Staphylococcus aureus (ATCC 25923), Pseudo-
monas aeruginosa (ATCC 27853), Bacillus subtilis (ATCC
6633), Enterococcus faecalis (ATCC 29212), methicillin-
resistant Staphylococcus aureus (MRSA) (ATCC 33591),
vancomycin-resistant Enterococcus faecalis (VRE) (ATCC
51299) and vancomycin-resistant Enterococcus faecium
(VRE) (ATCC 700221). The ATCC strains used were able
to produce biofilms in a given conditions. A stable non-
biofilm producing clinical isolate Staphylococcus aureus
(mutant) was used in the bioassays as control.
Inocula preparation
All the bacterial strains were recovered on a fresh tryptic
soy agar (Difco, USA) plate 24 h prior to antimicrobial
test. To prepare the inoculum, colonies from fresh tryptic
soy agar were transferred into sterile Mueller Hinton (MH)
liquid growth medium and incubated at 37°C overnight.
Aliquots (500 μl) were transferred to 10 ml of fresh MH
broth and incubated at 37°C. The optical density 600 nm
wavelength (OD600) was monitored until the exponential
growth phase was reached. Cells were harvested by centri-
fugation (3,000 g, 5 min at 4°C), washed in 10 mmol/L
phosphate-buffered saline (PBS) (pH 7.4), and resuspended
in MH broth to an approximate cell density of 1.0 ×
105 CFU/ml. The final cells concentration was confirmed
by viable counts.
Minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC)
The minimum inhibitory concentrations (MIC) of E. hirta
were determined by using tetrazolium microplate assay
which were slightly modified from serial broth microdilu-
tion method as described by Eloff [17]. This assay was per-
formed using Corning 35–1172 flat-bottomed polystyrene
96-well clear microtitre plates with standard plate layout
as proposed by Cos et al. [18]. Briefly, methanol extract of
E. hirta were dissolved in DMSO and an identical two-
fold serial dilution using MH broth were made to form0.062 – 2.0 mg/ml. One hundred microlitres of bacterial
inoculum was added and mixed thoroughly in all the wells
(0.031 – 1.0 mg/ml as the highest in-test concentration.
The microtitre plates were sealed with parafilm tape and
incubated overnight at 37°C. An appropriate mixture of
solvent DMSO, medium and inoculum were included as
drug-free control and the final concentration of DMSO in
the well was ensured to be less than 1% (v/v). Clinically
established antibiotic, cefepime was used in parallel ex-
periment as a positive drug control. An additional non-
infected medium was included for sterility check. The
MIC of E. hirta extract was detected following addition of
50 μl of INT (2-4-Iodophenyl-3-4-nitrophenyl-5-phenyl-
2H-tetrazolium chloride) at a final concentration 0.2 mg/ml
in all the wells and incubated for further 30 min at 37°C.
Bacterial growth was determined by observing the color
change of INT in the microplate wells. Biologically active
bacterial cells will reduce the colourless tetrazolium salt
which act as an electron acceptor to a red-coloured forma-
zan product [19]. Inhibition of bacterial growth is observed
when the solution in the well remained clear after in-
cubation with INT. MIC was defined as the lowest ex-
tract concentration that completely inhibits the growth
of microorganisms.
For the determination of minimum bactericidal con-
centration (MBC), 20 μl of culture medium from the mi-
crotitre plate wells that showed no changes in color will
be re-inoculated on MH agar plates. After 24 h of incu-
bation at 37°C, MBCs were determined as the lowest
concentration that yielded nil bacterial growth on MH
agar plates. The MIC and MBC determination were per-
formed three times in duplicate.
Inhibition of biofilm formation
The effect of E. hirta extract to inhibit biofilm formation
was measured using microplate based assay, modified
from Stepanovic et al. [20]. Briefly, the bacterial cells were
grown in tryptic soy broth (TSB) at 37°C overnight. The
cultures was then harvested by centrifugation (14,000 rpm,
15 min at 4°C) and rinsed with phosphate-buffered saline
(PBS, pH 7.4). The washed bacterial cells were then resus-
pended in tryptic soy broth to approximately 1 × 107 cfu/
ml (determined by OD and plate count assay). Two-fold
serial dilution of E. hirta extract was made with TSB to
achieve concentrations ranging from 0.062 – 2.0 mg/ml.
An amount of 40 μL of the E. hirta extract solution was
then pre-mixed with the bacterial inocula (360 μL) to at-
tain final concentration ranging from 0.031 – 1.0 mg/ml.
One hundred microliters of this mixture for each concen-
tration was added to three separate wells in the 96-well
microplates for replicate testing. Wells containing mixture
of dilute DMSO and inoculum were included as control
with DMSO final concentration of 1% (v/v). After 24 h of
incubation at 37°C, the supernatant containing TSB and
Table 1 Chemical composition of methanol extract of
Euphorbia hirta
N0. Compounda RTb Composition (%)
1 Megastigmatrienone 6.711 0.1
2 6,10,14-Trimethyl-2-Pentadecanone 7.803 0.1
3 Methyl palmitate 8.202 1.1
4 Methyl ester of 3-(3,5-di-tert-butyl-4-
hydroxyphenyl)-propionic acid
8.349 0.4
5 Palmitic acid 8.426 7.2
6 Methyl linolenate 9.071 1.9
7 Phytol 9.127 8.5
8 Linoleic acid 9.288 7.7
9 2-monopalmitin 10.856 4
10 2-monostearin 11.906 2.2
11 Squalene 12.628 2.2
12 Vitamin-E 15.645 1
13 Neophytadiene 15.849 0.2
14 Campesterol 17.06 1.9
15 Clionasterol 18.607 10.4
16 Alnulin or skimmiol 18.943 2.5
17 Beta-amyrin 19.273 3.1
18 Cycloartenol 20.078 34.7
19 Alpha-amyrin 20.295 10.7











aCompounds are listed in order of elution from a HP-5 MS column.
bRetention time (as minutes).
Perumal and Mahmud BMC Complementary and Alternative Medicine 2013, 13:346 Page 4 of 8
http://www.biomedcentral.com/1472-6882/13/346planktonic cells were gently removed from the microplate
wells and the wells were washed twice with 150 μL of PBS.
After rinsing, 30 μl of the INT reagent were added and the
suspension was incubated for 4 h at 37°C. The minimum
biofilm inhibitory concentration (MBIC), defined as the
lowest concentration of an antimicrobial agent required to
inhibit the formation of biofilms was determined by ob-
serving the color change of INT in the microplate wells as
described above. Non-biofilm forming clinical isolate S.
aureus was used as negative control and wells containing
clinically established drug (cefepime) were used as positive
control. The bioassay was performed in triplicate.
Eradication of biofilms
In order to test the ability of E. hirta extract to eradicate
the formed biofilms, a modified microdilution assay de-
scribed by LaPlante [21] was employed. Microbial biofilms
were developed in flat bottom 96-well clear microtitre
plates. A volume of 30 μl of a washed suspension of bac-
terial cells grown into the mid exponential phase in tryptic
soy broth (1.0 × 105 CFU/ml) were inoculated into fresh
tryptic soy broth at 150 μL/well. The cultured microtitre
plates were incubated at 37°C to permit the microbial cells
to form the biofilms. After 24 hours of biofilm growth, the
wells were rinsed with PBS (pH 7.4) to remove non-
adherent cells. The biofilms established for 24 hours in the
each well were subsequently treated with two-fold serial
dilutions of E. hirta extract (1 mg/ml as the highest in-test
concentration). Non-biofilm isolate was used as negative
control and wells containing clinically established drugs
were used as positive control. The microtitre plates were
sealed with parafilm tape and incubated overnight at 37°C.
The minimal biofilm eradication concentration (MBEC),
defined as the lowest concentration of an antimicrobial
agent required to eradicate biofilm, was determined by ob-
serving the color change of INT in the microplate wells as
per MIC determination method. The bioassay was per-
formed in triplicate.
Statistical analyses
The results were analyzed using Statistical Package for
the Social Sciences (SPSS) software version 17.0. All the
values are expressed as means ± standard deviation (SD)
from triplicate experiments.
Results
GC and GC–MS analyses
Analyses (GC and GC-MS) of aerial part of E. hirta
methanol extract enabled the identification of nineteen
chemical compounds showing more than 90% similarity
with the standard mass spectra in the library. The quali-
tative analytical results are shown in Table 1. This ex-
tract is characterized by the presence of diterpenes 8.7%,
triterpenes 16.0%, triterpenoids 12.9%, sterols 36.6%, tocols1%, esters 9.2%, fatty acids 15.3%, and ketones 0.3%. The
dominant compounds found in the extract were cycloarte-
nol (34.7%), alpha-amyrin (10.7%), clionasterol (10.4%),
phytol (8.5%), linoleic acid (7.7%), palmitic acid (7.2%) and
2-monopalmitin (4%). Other components were present in
amounts less than 4%. Squalene and megastigmatrienone
are being reported for the first from this spesies.Growth inhibition of planktonic cells
Initially, methanol extract of E. hirta was assessed on
growth inhibitory ability against planktonic cells of clinical
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tatively assessed by the MIC and MBC values (Table 2).
Among all the pathogen, P. aeruginosa was the most sus-
ceptible bacteria to E. hirta extract, with MIC and MBC
values of 0.062 mg/ml and 0.125 mg/ml, respectively. A
moderate growth inhibition was observed against E. faeca-
lis, Bacillus cereus and P. aeruginosa (ATCC 27853) with
MIC and MBC values of 0.125 mg/ml and 0.25 mg/ml, re-
spectively. This extract also displayed mild antibacterial ac-
tivities against S. typhi, B. subtilis and S. aureus (ATCC
25923) with MIC and MBC values of 0.25 mg/ml and
0.5 mg/ml, respectively. Compared to the positive control,
cefepime belonging to the β-lactam antibiotics which
is inhibitor of cell wall synthesis was found to possess
high inhibitory activity against most of bacteria under
investigation.Table 2 Biological activity of methanol extract of E. hirta (mg/m




Klebsiella pneumonia 1 >1
Pseudomonas aeruginosa 0.062 0.125
Salmonella typhi 0.25 0.5
Shigella dysenteriae 1 >1
Enterobacter aerogens 1 >1
Escherichia coli 0.5 >1
Enterococcus faecalis 0.125 0.25
Proteus mirabilis 0.5 >1
Proteus vulgaris 0.5 >1
Bacillus subtilis 0.25 0.5
Bacillus cereus 0.125 0.25
Non-biofilm producing
Staphylococcus aureus 0.125 0.25
Standard strain
Escherichia coli (ATCC 25922) 0.5 1
Staphylococcus aureus (ATCC 25923) 0.25 0.5
Pseudomonas aeruginosa (ATCC 27853) 0.125 0.25
Bacillus subtilis (ATCC 6633) 0.5 1
Enterococcus faecalis (ATCC 29212) 0.5 1
Methicillin-resistant staphylococcus aureus 0.5 1
(MRSA) (ATCC 33591)
Vancomycin-resistant enterococcus faecalis 0.5 >1
(VRE) (ATCC 51299)
Vancomycin-resistant enterococcus faecium 1 >1
(VRE) (ATCC 700221)
aValues expressed are mean ± standard deviation of three experiments; values given
bNA, not active.Biofilm inhibitory activities of E. hirta extract
The capability of methanol extract of E. hirta to attenu-
ate biofilm formation was shown in Table 2. The potent
biofilm inhibition activity was detected against clinical
isolate of P. aeruginosa with MBIC value of 0.25 mg/ml.
A good inhibition of adherence was observed in E. faeca-
lis and P. aeruginosa (ATCC 27853) with MBIC value of
0.5 mg/ml. The remainder of the biofilms recorded the
lowest resistance to this methanol extract (MBIC ≥ 1).
Within the tested MBIC range (0.031 to 1 mg/ml), cefe-
pime showed weak biofilm inhibitory activity against all
the pathogens.
Eradication of the established biofilm by E. hirta extract
E. hirta extract effectively eradicated the established bio-
film of P. aeruginosa, with minimum biofilm eradicationL) against resistant clinical isolates and standard strains
f Euphorbia hirta Cefepime
MBIC MBEC MIC MBC MBIC MBEC
>1 >1 0.031 0.062 1 >1
0.25 0.5 0.015 0.031 0.125 0.5
1 >1 0.062 0.125 0.5 >1
>1 >1 0.031 0.062 >1 >1
>1 >1 0.062 0.25 1 >1
1 >1 0.015 0.031 0.5 1
0.5 1 NA NA NA NA
>1 >1 0.031 0.125 >1 >1
1 >1 0.062 0.25 1 >1
1 >1 0.031 0.125 >1 >1
0.5 >1 NA NA NA NA
0.25 0.5 0.015 0.031 0.5 1
>1 >1 0.015 0.031 0.5 1
1 >1 0.015 0.062 0.25 1
0.5 1 0.031 0.062 0.5 1
1 >1 0.125 0.5 1 >1
>1 >1 NA NA NA NA
1 >1 0.062 0.125 0.5 >1
1 >1 NA NA NA NA
>1 >1 0.125 0.25 >1 >1
as mg/ml.
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extract also showed weak anti-biofilm activities against
E. faecalis and P. aeruginosa (ATCC 27853) exhibiting
MBEC value of 1.0 mg/ml. Nevertheless, E. hirta extract
displayed no capability to disrupt the established biofilm
in the rest of the selected pathogens at the highest test
concentration of 1 mg/ml. Cefepime found to be ineffect-
ive to eradicate biofilm of all the tested pathogens except
for the clinical isolate, P. aeruginosa with MBEC value of
0.5 mg/ml.
Discussion
Biofilm infections represent a serious health threats world-
wide today mostly due to the appearance of antibiotic
resistant strains. Contemporary testing on minimum in-
hibitory concentration (MIC) which measures only plank-
tonic susceptibility may be the possible explanation for
treatment failures and resistant development among bac-
terial biofilms. In the present study, the results of the MIC,
MBC, MBIC and MBEC have highlighted the interesting
activity of E. hirta. The phytochemicals present in the
crude methanolic extract of E. hirta plays an important
role for the evident antibacterial and anti-biofilm activity.
Medicinal plants are rich of secondary metabolites which
some of them are directly involved in plant defense mech-
anisms against microorganisms [22]. In the current investi-
gation, GC-MS analysis of methanol extract of E. hirta
aerial part was conducted with the intention to correlate
the phytochemical compounds to the antibacterial and
anti-biofilm activity. The GC-MS profile of methanol ex-
tract of E. hirta revealed the presence of nineteen com-
pounds. The most abundant phytocompound found was
terpenoids. Terpenoids are the largest group of natural
plant products many of which well acknowledged as po-
tential antimicrobial agents. It is feasible that the observed
broad spectrum antibacterial activity by methanolic ex-
tract of E. hirta probably attributed to the dominant
presence of some terpenoids (cycloartenol, squalene, α-
amyrin and β-amyrin). Previous studies have shown α-
amyrin and β-amyrin were potential to inhibit the growth
of some microbes [23,24]. These terpenoids most likely in-
volved in the detachment of planktonic cells from the bio-
film. Probably the terpenoids influenced the membrane
integrity in all organisms and helped to eradicate most
biofilm cells. The significant reduction in cell attachment
made terpenoids an ideal anti-adhesive compound. Ter-
penes have also been frequently reported to be active
against bacteria [25]. The mechanism of action of terpenes
is thought to involve membrane disruption by the lipo-
philic compounds and thereby inhibit respiration and ion
transport processes in the bacterial cells [22]. De Carvalho
et al., [26] proved that natural compounds such as ter-
penes can be used to prevent cell aggregation and biofilm
formation. Terpenes are believed to influence the fattyacid composition of the cell membrane, and thus cell
hydrophobicity which lead to the eradication of the bio-
film. Additionally, the expression of synergy, antagonism
or additive effects among the major phytocompounds
found in the crude extract may also be the rationale to the
apparent anti-biofilm activity. The standard antibiotic (ce-
fepime) used in this study showed potent antibacterial and
anti-biofilm activity due to the fact that they appeared in
purest form in contrast to the crude extract which is in
complex mixtures of compounds. The MIC of the stand-
ard antibiotic used as positive control is given in Table 2.
GC-MS analysis helps towards comprehending the phyto-
compounds with remedial values in E. hirta.
To begin our investigation on antibacterial activities,
the growth inhibition effect of E. hirta methanolic ex-
tract were determined first on planktonic cultures of re-
sistant clinical isolates and standard strains. E. hirta
extract exerted broad antibacterial spectrum with sub-
stantial potency against both Gram-positive and Gram-
negative bacteria tested. The standard strains presented
more invulnerability towards E. hirta methanol extracts
compared to resistant clinical isolates. This is due to
ATCC strains are well characterized cultures with higher
stability towards the antimicrobials. The strongest inhib-
ition was recorded against Gram negative, P. aeruginosa
followed by moderate antibacterial activity against Gram
positive, E. faecalis and B. cereus. The different cell wall
susceptibility amongst bacteria may be the key contributor
to various MIC and MBIC values. According to Fennel
et al., [27], Gram positive bacteria are often found to be
more susceptible to plant extracts than the Gram negative
bacteria. It is well known that the outer membrane
present only in the Gram negative bacteria play an import-
ant role as an effective barrier. However in this study, the
prominent sensitivity of P. aeruginosa toward methanolic
extract of E. hirta may possibly due to the membrane per-
meability. Similar results for the effect of essential oils on
outer membrane permeability in Gram-negative bacteria
were reported by Helander et al., [28]. Although Gram
positive bacteria lack of outer membrane, the thicker cell
wall consist of few peptidoglycan layers could act as func-
tional barrier thus hinder the penetration of antimicrobial
compound into the bacterial cell [29]. E. hirta extract dis-
played a distinct bactericidal mode of action against most
of the bacteria tested. The bactericidal activity is con-
firmed by the obtained MBC values which are usually two
to four higher than the corresponding MICs. The MIC
and MBC values reported in this work were lower than
those obtained from other studies involving E. hirta plant
[10,30].
In contrast to the growth inhibitory ability against plank-
tonic cells, biofilms of P. aeruginosa were less susceptible
to E. hirta extract with MBIC value of 0.25 mg/ml. Bac-
teria living as biofilm are often more difficult to eradicate
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cells forms biofilms by adhering to each other strongly via
formation of pili. Apparently, in this study, the pilicides ac-
tion of E. hirta methanolic extract might be the reason for
the growth inhibition of P. aeruginosa biofilm. Besides pili
formation, bacteria also use quorum sensing to coordinate
the formation of biofilms. Quorum sensing (QS) is a cell-
to-cell signaling mechanism which often linked to the es-
tablishment of complex communities of bacteria. The QS
present between the bacterial inhabitants has led to devel-
opment of the biofilms [31]. The opportunistic pathogen
P. aeruginosa uses quorum sensing to coordinate the for-
mation of biofilms, swarming motility, exopolysaccharide
production, and cell aggregation [32]. The eradication of
P. aeruginosa biofilm was interpreted to suggest that meth-
anolic extract of E. hirta displays QS inhibitory activity.
MBIC and MBEC values of E. hirta methanol extract
against clinical isolates and standard strains are being doc-
umented for the first time in this study. This study outlines
a very sturdy basis for future investigations in pursuit to
discover new anti-infectious agents.
Conclusions
In conclusion, the findings from this study seemed to
validate the traditional use of E. hirta plant for the treat-
ment of ailments caused by infectious agents. The inter-
esting biofilm inhibitory and eradication activity found
against P. aeruginosa biofilm makes this ethnomedicinal
plant an outstanding candidate for nosocomial infection
therapy. Moreover, E. hirta plant may also benefit the
hospitals and healthcare facilities as biofilm control agents
for the prevention of contamination in the medical devises.
The antibacterial and anti-biofilm activities of crude ex-
tract of E. hirta plant could be further improved after the
opportune bioactivity guided fractionation steps. This pace
may help to discover and develop distinctive chemical en-
tities with above promising biological activities.
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